Wedbush Reiterates Outperform on Adicet Bio, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Robert Driscoll has reiterated an 'Outperform' rating on Adicet Bio (NASDAQ:ACET) and maintained a $17 price target.
August 10, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst maintains 'Outperform' rating and $17 price target on Adicet Bio.
The reiteration of the 'Outperform' rating and the maintenance of the $17 price target by Wedbush analyst Robert Driscoll indicates a positive outlook for Adicet Bio. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100